Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.38 |
| ▸ | TRPC3 | Q13507 | 2/20 | 0.35 |
| ▸ | TRPC6 | Q9Y210 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.33 |
| ▸ | ATR | Q13535 | 2/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | FLT3 | P36888 | 2/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.32 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.32 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21470492 | 0.85 | KDM5B (0.38) | KDM5BALDH1A1LMNAPOLBCYP4F2 | |
| SCHEMBL21465725 | 0.81 | KDM5B (0.39) | KDM5BALDH1A1LMNAPOLBCYP4F2 | |
| SCHEMBL23353704 | 0.79 | KDM5B (0.37) | KDM5BALDH1A1LMNAPOLBCYP4F2 | |
| SCHEMBL31180433 | 0.78 | KDM5B (0.36) | KDM5BALDH1A1LMNAPOLBCYP4F2 | |
| SCHEMBL31510378 | 0.78 | KDM5B (0.35) | KDM5BALDH1A1LMNAPOLBCYP4F2 | |
| SCHEMBL29794329 | 0.77 | ACHE (0.44) | TRPC3TRPC6PKM | |
| SCHEMBL21962281 | 0.76 | CYP4F2 (0.40) | KDM5BALDH1A1LMNAPOLBCYP4F2 | |
| SCHEMBL20237038 | 0.76 | KDM5B (0.40) | KDM5BALDH1A1LMNAPOLBCYP4F2 | |
| SCHEMBL12552172 | 0.76 | MPO (0.43) | KDM5BALDH1A1LMNAPOLBCYP4F2 | |
| SCHEMBL16353569 | 0.76 | ALDH1A1 (0.44) | KDM5BALDH1A1LMNAPOLBCYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118055926-A | ROCK2 inhibitors and uses thereof | 哈佛大学的校长及成员们 | 2024-05-17 | — | — | CN | disclosed |
| EP-4204415-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2023-07-05 | — | — | EP | disclosed |
| WO-2022042691-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2022-03-03 | — | — | WO | disclosed |
| EP-2807162-B1 | SUBSTITUTED PHENYLIMIDAZOPYRAZOLES AND USE THEREOF | Bayer Pharma AG (DE) | 2017-06-07 | — | — | EP | disclosed |
| EP-2807162-B1 | SUBSTITUTED PHENYLIMIDAZOPYRAZOLES AND USE THEREOF | Bayer Pharma AG (DE) | 2017-06-07 | — | — | EP | disclosed |
| US-9394309-B2 | Substituted phenylimidazopyrazoles and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-07-19 | — | — | US | disclosed |
| US-9394309-B2 | Substituted phenylimidazopyrazoles and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-07-19 | — | — | US | disclosed |
| US-9394309-B2 | Substituted phenylimidazopyrazoles and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-07-19 | — | — | US | disclosed |
| US-20150005288-A1 | SUBSTITUTED PHENYLIMIDAZOPYRAZOLES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-01-01 | — | — | US | disclosed |
| US-20150005288-A1 | SUBSTITUTED PHENYLIMIDAZOPYRAZOLES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-01-01 | — | — | US | disclosed |
| US-20150005288-A1 | SUBSTITUTED PHENYLIMIDAZOPYRAZOLES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-01-01 | — | — | US | disclosed |
| EP-2807162-A1 | SUBSTITUTED PHENYLIMIDAZOPYRAZOLES AND USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2014-12-03 | — | — | EP | disclosed |
| WO-2013144191-A1 | SUBSTITUTED 2-AMINO-3-CYANOPYRIDINES AS INHIBITORS OF SODIUM-CALCIUM EXCHANGE AND USE THEREOF FOR CARDIOVASCULAR DISEASES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-10-03 | — | — | WO | disclosed |
| WO-2013144191-A1 | SUBSTITUTED 2-AMINO-3-CYANOPYRIDINES AS INHIBITORS OF SODIUM-CALCIUM EXCHANGE AND USE THEREOF FOR CARDIOVASCULAR DISEASES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-10-03 | — | — | WO | disclosed |
| WO-2013110590-A1 | SUBSTITUTED PHENYLIMIDAZOPYRAZOLES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-08-01 | — | — | WO | disclosed |
| WO-2013110590-A1 | SUBSTITUTED PHENYLIMIDAZOPYRAZOLES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-08-01 | — | — | WO | disclosed |
| US-20130190290-A1 | Substituted phenylimidazopyrazoles and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-25 | — | — | US | disclosed |
| US-20130190290-A1 | Substituted phenylimidazopyrazoles and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-25 | — | — | US | disclosed |
| US-20130190290-A1 | Substituted phenylimidazopyrazoles and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005288-A1 | SUBSTITUTED PHENYLIMIDAZOPYRAZOLES AND USE THEREOF | VHL, FLT4, FLT1 | KDM5B 3565/4885TRPC3 3058/4885TRPC6 4823/4885 |
| US-20130190290-A1 | Substituted phenylimidazopyrazoles and their use | VHL, FLT4, FLT1 | KDM5B 3666/4885TRPC3 3124/4885TRPC6 4819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.